Mountain Capital Investment Advisors’s Nektar Therapeutics NKTR Stock Holding History

Mountain Capital Investment Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-667	Closed	-$39K	–	87
2022 Q2	$39K	Hold	667	–	–	0.02%	75
2022 Q1	$56K	Hold	667	–	–	0.03%	88
2021 Q4	$124K	Hold	667	–	–	0.06%	117
2021 Q3	$170K	Hold	667	–	–	0.09%	122
2021 Q2	$168K	Hold	667	–	–	0.08%	120
2021 Q1	$187K	Hold	667	–	–	0.09%	144
2020 Q4	$187K	Sell	667 -66	-9%	-$17.1K	0.11%	134
2020 Q3	$190K	Hold	733	–	–	0.12%	97
2020 Q2	$266K	Buy	733 +66	+10%	+$20.6K	0.12%	42
2020 Q1	$188K	Hold	667	–	–	0.1%	42
2019 Q4	$218K	Hold	667	–	–	0.1%	41
2019 Q3	$182K	Buy	+667	New	+$245K	0.16%	47

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Mountain Capital Investment Advisors's NKTR Position: Q3 2022 in Review

Mountain Capital Investment Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 667 shares — an estimated $39K sold.

Mountain Capital Investment Advisors first reported a position in NKTR in Q3 2019 and held it in 12 quarters. The position peaked at $266K in Q2 2020. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

Mountain Capital Investment Advisors reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
Mountain Capital Investment Advisors sold 667 Nektar Therapeutics shares in Q3 2022, an estimated $39K.
Mountain Capital Investment Advisors first reported a position in Nektar Therapeutics in Q3 2019 and held it in 12 quarters.
Mountain Capital Investment Advisors's Nektar Therapeutics position peaked at $266K in Q2 2020.
230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Mountain Capital Investment Advisors's 13F filing for Q3 2022, filed 20 Oct 2022.